Publications by authors named "Andrew Lassman"

Claim this Profile
S
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
Howard Colman, Giuseppe Lombardi, Eric T Wong, Tobias Walbert, Marica Eoli, Andrew B Lassman

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Immune Check Point Blockade in -Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
Andrew B Lassman, Mei-Yin C Polley, Fabio M Iwamoto, Andrew E Sloan, Tony J C Wang

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
Patrick Y Wen, Michael Weller, Eudocia Q Lee, Mehdi Touat, Mustafa Khasraw, Andrew B Lassman

Neuro Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update.
Jaishri Blakeley, Nimish A Mohile, Hans Messersmith, Andrew B Lassman, David Schiff

Neuro Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update.
Jaishri Blakeley, Nimish A Mohile, Hans Messersmith, Andrew B Lassman, David Schiff

J Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-radiation targeted therapy for highly selected patients with newly diagnosed glioblastoma: New tricks for an old dog?
Macarena I de la Fuente, Andrew B Lassman

Neuro Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update Clinical Insights.
Nimish A Mohile, Andrew B Lassman, David Schiff, Jaishri Blakeley

JCO Oncol Pract· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply.
Benjamin M Ellingson, Francesco Sanvito, Whitney B Pope, Timothy F Cloughesy, Raymond Y Huang, Andrew B Lassman

AJNR Am J Neuroradiol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults.
Benjamin M Ellingson, Francesco Sanvito, Timothy F Cloughesy, Raymond Y Huang, Javier E Villanueva-Meyer, Andrew B Lassman

AJNR Am J Neuroradiol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
Isabel Arrillaga-Romany, Andrew Lassman, Susan L McGovern, Sabine Mueller, Burt Nabors

Neuro Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.
Colin J Vize, Stella K Kim, Tim Matthews, Marian Macsai, Ryan Merrell, Andrew B Lassman

Ophthalmic Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Patrick Y Wen, Martin van den Bent, Gilbert Youssef, Timothy F Cloughesy, Benjamin M Ellingson, Andrew B Lassman

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Benjamin M Ellingson, Patrick Y Wen, Susan M Chang, Martin van den Bent, Michael A Vogelbaum, Andrew B Lassman

Neuro Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is a glioblastoma?
Andrew B Lassman, Martin J van den Bent

Neuro Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Prabhjot S Mundi, Filemon S Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Andrew B Lassman

Cancer Discov· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.
Maximilian J Mair, Rupert Bartsch, Emilie Le Rhun, Anna S Berghoff, Priscilla K Brastianos, Andrew B Lassman

Nat Rev Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-convolving the compositional landscape of primary and recurrent glioblastoma reveals prognostic and targetable tissue states.
Osama Al-Dalahmah, Michael G Argenziano, Adithya Kannan, Aayushi Mahajan, Julia Furnari, Andrew B Lassman

Nat Commun· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.
Priya U Kumthekar, Michael J Avram, Andrew B Lassman, Nancy U Lin, Eudocia Lee

Neuro Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
Andrew B Lassman, Stephanie L Pugh, Tony J C Wang, Kenneth Aldape, Hui K Gan

Neuro Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors.
Roberta Rudà, David Capper, Adam D Waldman, Johan Pallud, Giuseppe Minniti, Andrew B Lassman

Neuro Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Benedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, Andrew B Lassman, Saiama N Waqar

Neurooncol Adv· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial.
Eleonora F Spinazzi, Michael G Argenziano, Pavan S Upadhyayula, Matei A Banu, Justin A Neira, Andrew B Lassman

Lancet Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors.
Benjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, Caroline Chung, Howard Colman

Neuro Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.
Andrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, Alba A Brandes, J Gregory Cairncross

J Clin Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Andrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, Miguel J Gil-Gil, Vinay K Puduvalli

Clin Cancer Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis